Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

Sara Alosaimy,Taylor Morrisette,Abdalhamid M. Lagnf,Leonor M. Rojas,Madeline A. King,Benjamin M. Pullinger,Athena L. V. Hobbs,Nicholson B. Perkins,Michael P. Veve,Jeannette Bouchard,Tristan Gore,Bruce Jones,James Truong,Justin Andrade,Glen Huang,Reese Cosimi,S. Lena Kang-Birken,Kyle C. Molina,Mark Biagi,Michael Pierce,Marco R. Scipione,Jing J. Zhao,Susan L. Davis,Michael J. Rybak
DOI: https://doi.org/10.1128/spectrum.00479-22
IF: 3.7
2022-10-26
Microbiology Spectrum
Abstract:Acinetobacter baumannii , particularly when carbapenem resistant (CRAB), is one of the most challenging pathogens in the health care setting. This is complicated by the fact that there is no consensus guideline regarding management of A. baumannii infections.
microbiology
What problem does this paper attempt to address?